查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1465007

金諾芬市場：依形式、適應症分類 - 2024-2030 年全球預測

Auranofin Market by Form (Capsule, Tablet), Indication (Seronegative Rheumatoid Arthritis, Seropositive Rheumatoid Arthritis) - Global Forecast 2024-2030
出版日期: | 出版商: 360iResearch | 英文 191 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計2023年金諾芬市場規模為2.092億美元，預計2024年將達2.1899億美元，2030年將達2.9085億美元，複合年成長率為4.81%。

金諾芬是一種含金口服化合物，被歸類為緩解疾病抗風濕藥物 (DMARD)。它被開發用於治療類風濕性關節炎是一種以發炎和疼痛為特徵的慢性自體免疫疾病。金諾芬調節免疫系統，減少發炎並減緩疾病進展。此外，其免疫調節特性促使人們研究其對抗其他自體免疫疾病和某些類型癌症的潛在功效。另一方面，儘管它具有治療功效，但它的使用通常會仔細權衡潛在的副作用，例如腎臟和肝損傷，並且在治療期間需要定期監測患者。金諾芬是一種治療自體免疫疾病的獨特方法，強調了平衡慢性病管理中療效和安全性的重要性。類風濕性關節炎的盛行率不斷上升，以及在抗藥性不斷增加的情況下對替代療法的需求是根本促進因素。研究進展顯示金諾芬對某些癌症和寄生蟲有效，這將進一步擴大市場。此外，政府和非政府對慢性病和癌症研究的資助在市場擴張中發揮重要作用。然而，與金諾芬相關的副作用，例如胃腸道紊亂和皮膚反應，限制了一些患者對其的接受度。新應用的監管障礙和臨床試驗的高成本也是主要挑戰。探索金諾芬在腫瘤學和寄生蟲學中的應用帶來了巨大的成長機會。對抗藥性癌症和寄生蟲的功效潛力可能會開拓新的市場領域。此外，製藥公司和研究機構之間旨在擴大金諾芬用途的合作也將促進進一步的成長。

主要市場統計
基準年[2023] 2.092 億美元
預測年份 [2024] 21899萬美元
預測年份 [2030] 29085萬美元
複合年成長率（%） 4.81%

形式：金諾芬膠囊確保均勻分佈，適合將活性劑輸送到全身。

金諾芬膠囊主要被認為是專為治療類風濕性關節炎而設計的口服治療選擇。膠囊的便利性使其適合難以服用其他劑型的患者。金諾芬膠囊可實現全身藥物輸送並確保全身均勻分佈。金諾芬膠囊因其減少發炎、改善關節活動範圍和減輕疼痛的能力而受到特別關注，其劑量和給藥方案針對患者依從性和治療效果進行了最佳化。金諾芬錠劑提供了一種治療類風濕類風濕性關節炎的客製化方法，結合了易用性和精確的劑量控制。錠劑因其便攜性、穩定性以及能夠摻入可改善金諾芬藥物動力學特徵的控制釋放製劑的能力而受到高度優選。這意味著體內的藥物水平隨著時間的推移而更加穩定，這可以改善患者的治療效果並減少副作用。錠劑還可以促進對治療計劃的依從性，這是慢性病長期管理的重要因素。

適應症：由於發炎涉及細胞機制，金諾芬是治療血清陽性 RA 的首選藥物。

血清陰性類風濕性關節炎（RA）是類風濕性關節炎的一種亞型，患者不具有類風濕性關節炎患者中常見的類風濕因子（RF）抗體或抗環瓜氨酸胜肽（抗CCP）抗體。儘管不存在這些抗體，血清陰性 RA 仍可導致嚴重的發炎和損傷。金諾芬是一種口服金化合物，由於其發炎特性而被用於治療血清陰性 RA。金諾芬透過調節免疫系統來減少發炎和疾病進展。血清陰性 RA 的金諾芬治療方法著重於症狀控制和關節損傷的預防，據我所知，缺乏特異性的生物標記給該亞型的診斷和治療帶來了挑戰。血清陽性類風濕性關節炎的特徵是患者血液中存在類風濕因子（RF）抗體和/或抗環瓜氨酸胜肽（抗CCP）抗體。這種類型的 RA 通常與更具侵襲性的病程相關，包括更嚴重的關節受累和關節外症狀的更高風險。金諾芬因其在控制血清陽性 RA 方面的作用而得到認可，因為它可以抑制發炎相關的細胞機制。透過針對導致發炎細胞激素產生的特定途徑，金諾芬有助於減輕受影響關節的發炎、腫脹和疼痛。雖然金諾芬不是 RA 的一線藥物，但它是對傳統緩解疾病抗風濕藥物 (DMARD) 或生物製藥不耐症或無反應的患者的一種治療選擇，並且是一種旨在減少疾病活動性和治療效果的治療選擇。

區域洞察

在美洲，特別是在美國和加拿大，金諾芬市場受到其長期用於治療類風濕性關節炎的推動。市場已經成熟，需求穩定，這主要是由於醫療基礎設施和報銷政策有利於開藥。然而，來自DMARD和生物相似藥等新生物製藥的競爭正在加劇，市場佔有率正在成為一個問題。在歐洲，重點放在成本效益和臨床表現上，嚴格的市場監管可能會限制金諾芬的成長潛力，儘管其功效已得到證實。儘管中東市場規模較小，但由於醫療基礎設施和投資的不斷擴大，它被視為一個充滿前景的市場。由於醫療保健系統的快速發展、患者意識的提高以及類風濕性關節炎盛行率的增加，預計亞太地區金諾芬市場將顯著成長。中國和印度等人口眾多且醫療環境改善的國家預計將對市場做出重大貢獻。此外，隨著該地區研究和開發活動的增加，預計會有新的治療應用。

FPNV定位矩陣

FPNV定位矩陣對於評估Auranofin市場至關重要。我們檢視與業務策略和產品滿意度相關的關鍵指標，以對供應商進行全面評估。這種深入的分析使用戶能夠根據自己的要求做出明智的決策。根據評估，供應商被分為四個成功程度不同的像限：前沿（F）、探路者（P）、利基（N）和重要（V）。

市場佔有率分析

市場佔有率分析是一種綜合工具，可以對 Auranofin 市場供應商的現狀進行深入而詳細的研究。全面比較和分析供應商在整體收益、基本客群和其他關鍵指標方面的貢獻，以便更好地了解公司的績效及其在爭奪市場佔有率時面臨的挑戰。此外，該分析還提供了對該行業競爭特徵的寶貴見解，包括在研究基準年觀察到的累積、分散主導地位和合併特徵等因素。詳細程度的提高使供應商能夠做出更明智的決策並制定有效的策略，以獲得市場競爭優勢。

本報告對以下幾個方面提供了寶貴的見解：

1. 市場滲透率：提供有關主要企業所服務的市場的全面資訊。

2. 市場開拓：我們深入研究利潤豐厚的新興市場，並分析其在成熟細分市場的滲透率。

3. 市場多元化：提供有關新產品發布、開拓地區、最新發展和投資的詳細資訊。

4.競爭力評估及資訊：對主要企業的市場佔有率、策略、產品、認證、監管狀況、專利狀況、製造能力等進行全面評估。

5. 產品開發與創新：提供對未來技術、研發活動和突破性產品開發的見解。

本報告解決了以下關鍵問題：

1.Auranofin市場的市場規模和預測是多少？

2.Auranofin市場預測期間需要考慮投資的產品、細分市場、應用和領域有哪些？

3. 金諾芬市場的技術趨勢和法規結構是什麼？

4.金諾芬市場主要供應商的市場佔有率是多少？

5. 進入金諾芬市場合適的形式和策略手段是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 類風濕性關節炎盛行率上升以及對替代治療的需求
      • 金諾芬對寄生蟲感染疾病、某些癌症和抗病毒藥物具有潛在作用
      • 政府和非政府資助慢性病和癌症研究
    • 抑制因素
      • 與金諾芬相關的副作用
    • 機會
      • 探索金諾芬在新治療應用的有效性
      • 製藥公司與研究機構的合作
    • 任務
      • 複雜的監管環境和高成本
  • 市場區隔分析
    • 形式：金諾芬膠囊的相容性，可將活性藥物輸送到全身並確保均勻分佈
    • 適應症：由於涉及發炎的細胞機制，金諾芬是治療血清陽性 RA 的首選藥物
  • 市場擾動分析
  • 波特五力分析
  • 價值鍊和關鍵路徑分析
  • 價格分析
  • 技術分析
  • 專利分析
  • 貿易分析
  • 法規結構分析

第6章 金諾芬市場：依形式

  • 膠囊
  • 藥片

第7章 金諾芬市場：依適應症分類

  • 血清陰性類風濕性關節炎
  • 血清陽性類風濕性關節炎

第8章 金諾芬美洲市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第9章 亞太地區金諾芬市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第10章 歐洲、中東和非洲金諾芬市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第11章競爭格局

  • 市場佔有率分析（2023）
  • FPNV定位矩陣（2023）
  • 競爭情境分析
    • 關節炎基金會投資 110 萬美元用於頑固性類風濕性關節炎研究
  • 戰略分析和建議

第12章競爭組合

  • 主要企業簡介
  • 主要產品系列
Product Code: MRR-F97DD5A7D98B

[191 Pages Report] The Auranofin Market size was estimated at USD 209.20 million in 2023 and expected to reach USD 218.99 million in 2024, at a CAGR 4.81% to reach USD 290.85 million by 2030.

Auranofin is a gold-containing, orally administered compound classified as a disease-modifying antirheumatic drug (DMARD). It was specifically designed for the treatment of rheumatoid arthritis, a chronic autoimmune situation characterized by inflammation and pain in the joints. Auranofin works by modulating the immune system to decrease inflammation and slows the progression of the disease. Additionally, its immunoregulatory properties have spurred research into its potential efficacy against other autoimmune disorders and certain types of cancer. Despite its therapeutic benefits, its use is often carefully weighed against potential side effects, including renal and hepatic impairment, necessitating regular monitoring of patients under treatment. Auranofin represents a unique approach to managing autoimmune diseases, emphasizing the importance of balancing efficacy with safety in chronic disease management. The rising prevalence of rheumatoid arthritis and the need for alternative treatments amidst growing drug resistance are fundamental growth drivers. Advances in research demonstrating auranofin's efficacy against certain cancers and parasites further expand its market. Moreover, governmental and non-governmental funding for chronic diseases and cancer research plays a significant role in market expansion. However, side effects associated with auranofin, such as gastrointestinal issues and dermatological reactions, limit its acceptability among some patients. Regulatory hurdles and the high cost of clinical trials for new applications are significant challenges. The exploration of Auranofin's application in oncology and parasitology presents significant growth opportunities. Its potential effectiveness against drug-resistant cancers and parasites could open new market segments. Additionally, partnerships between pharmaceutical companies and research institutions aimed at expanding Auranofin's applications could spur further growth.

KEY MARKET STATISTICS
Base Year [2023] USD 209.20 million
Estimated Year [2024] USD 218.99 million
Forecast Year [2030] USD 290.85 million
CAGR (%) 4.81%

Form: Suitability of auranofin capsules to provide a systemic delivery of the active drug, ensuring a uniform distribution

Auranofin in capsule form is a recognized oral treatment option primarily designed for the management of rheumatoid arthritis. The convenience of capsule administration makes it suitable for patients who may have difficulty with other forms of medication. Auranofin capsules provide a systemic delivery of the active drug, ensuring a uniform distribution throughout the body. This form is particularly noted for its effectiveness in reducing inflammation, improving joint mobility, and decreasing pain with a dosage and administration schedule that is optimized for patient compliance and therapeutic efficacy. The tablet form of auranofin offers a tailored approach to the treatment of rheumatoid arthritis, combining ease of use with precise dosage control. Tablets are highly favored for their portability, stability, and ability to incorporate controlled-release formulations, which can improve the pharmacokinetic profile of auranofin. This means a more consistent drug level in the body over time, potentially leading to improved patient outcomes and reduced side effects. The tablet form can also facilitate adherence to treatment schedules, an important factor in the long-term management of chronic conditions.

Indication: Preference for auranofin in managing seropositive RA owing to its cellular mechanisms involved in inflammation.

Seronegative rheumatoid arthritis (RA) refers to a subtype of rheumatoid arthritis where the blood of the patient does not contain rheumatoid factor (RF) or anti-cyclic citrullinated peptide (anti-CCP) antibodies, which are typically found in rheumatoid arthritis patients. Despite the absence of these antibodies, seronegative RA can still cause significant joint inflammation and damage. Auranofin, an oral gold compound, has been utilized in the management of seronegative RA for its anti-inflammatory properties. It functions by modulating the immune system, thus reducing the inflammation and progression of the disease. Treatment approaches with auranofin in seronegative RA emphasize controlling symptoms and preventing joint damage, acknowledging the challenges in diagnosing and managing this subtype due to the lack of specific biomarkers. Seropositive Rheumatoid Arthritis is characterized by the presence of rheumatoid factor (RF) and/or anti-cyclic citrullinated peptide (anti-CCP) antibodies in the patient's blood. This form of RA is often associated with a more aggressive disease course, including more significant joint damage and a higher risk of developing extra-articular manifestations. Auranofin's role in managing seropositive RA has been recognized due to its capacity to inhibit cellular mechanisms involved in inflammation. By targeting specific pathways that lead to the production of pro-inflammatory cytokines, auranofin helps in reducing inflammation, swelling, and pain in affected joints. Although it is not among the first-line treatments for RA, Auranofin presents a therapeutic option for patients intolerant or unresponsive to conventional disease-modifying antirheumatic drugs (DMARDs) or biologic agents, aiming to reduce disease activity & improve the quality of life of patients with seropositive RA.

Regional Insights

In the Americas, particularly in the United States and Canada, the market for auranofin has been driven by its prolonged use in treating chronic rheumatoid arthritis. The market is mature with a stable demand, largely due to the established healthcare infrastructure and reimbursement policies favoring the drug's prescription. However, growing competition from newer biologic DMARDs and biosimilars poses challenges to its market share. In Europe, the market is highly regulated with a strong emphasis on cost-effectiveness and clinical outcomes, which could limit the growth potential of Auranofin despite its proven efficacy. The Middle East, while smaller in market size, shows promise due to growing healthcare infrastructure and investment. The Asia Pacific region is anticipated to depict significant growth for the auranofin market due to rapidly evolving healthcare systems, increasing patient awareness, and growing prevalence of rheumatoid arthritis. Countries including China and India, with their vast populations and improving healthcare settings, are expected to contribute substantially to the market. Furthermore, the region's increasing research and development activities may offer new opportunities for Auranofin in alternative therapeutic applications.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Auranofin Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Auranofin Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Auranofin Market, highlighting leading vendors and their innovative profiles. These include Chugai Pharmaceutical Co Ltd, LGM Pharma, Prometheus Laboratories Inc., Sebela Pharmaceuticals Inc., Taj Pharmaceuticals Limited, and Xediton Pharmaceuticals.

Market Segmentation & Coverage

This research report categorizes the Auranofin Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Form
    • Capsule
    • Tablet
  • Indication
    • Seronegative Rheumatoid Arthritis
    • Seropositive Rheumatoid Arthritis
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Auranofin Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Auranofin Market?

3. What are the technology trends and regulatory frameworks in the Auranofin Market?

4. What is the market share of the leading vendors in the Auranofin Market?

5. Which modes and strategic moves are suitable for entering the Auranofin Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising prevalence of rheumatoid arthritis and the need for alternative treatments
      • 5.1.1.2. Auranofin's potential against parasitic infections, certain cancers, and as an antiviral agent.
      • 5.1.1.3. Governmental and non-governmental funding for chronic diseases and cancer research
    • 5.1.2. Restraints
      • 5.1.2.1. Side effects associated with Auranofin
    • 5.1.3. Opportunities
      • 5.1.3.1. Exploring auranofin's efficacy in new therapeutic applications
      • 5.1.3.2. Partnerships between pharmaceutical companies and research institutions
    • 5.1.4. Challenges
      • 5.1.4.1. Complex regulatory landscape and the high cost of clinical trials
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Form: Suitability of auranofin capsules to provide a systemic delivery of the active drug, ensuring a uniform distribution
    • 5.2.2. Indication: Preference for auranofin in managing seropositive RA owing to its cellular mechanisms involved in inflammation.
  • 5.3. Market Disruption Analysis
  • 5.4. Porter's Five Forces Analysis
    • 5.4.1. Threat of New Entrants
    • 5.4.2. Threat of Substitutes
    • 5.4.3. Bargaining Power of Customers
    • 5.4.4. Bargaining Power of Suppliers
    • 5.4.5. Industry Rivalry
  • 5.5. Value Chain & Critical Path Analysis
  • 5.6. Pricing Analysis
  • 5.7. Technology Analysis
  • 5.8. Patent Analysis
  • 5.9. Trade Analysis
  • 5.10. Regulatory Framework Analysis

6. Auranofin Market, by Form

  • 6.1. Introduction
  • 6.2. Capsule
  • 6.3. Tablet

7. Auranofin Market, by Indication

  • 7.1. Introduction
  • 7.2. Seronegative Rheumatoid Arthritis
  • 7.3. Seropositive Rheumatoid Arthritis

8. Americas Auranofin Market

  • 8.1. Introduction
  • 8.2. Argentina
  • 8.3. Brazil
  • 8.4. Canada
  • 8.5. Mexico
  • 8.6. United States

9. Asia-Pacific Auranofin Market

  • 9.1. Introduction
  • 9.2. Australia
  • 9.3. China
  • 9.4. India
  • 9.5. Indonesia
  • 9.6. Japan
  • 9.7. Malaysia
  • 9.8. Philippines
  • 9.9. Singapore
  • 9.10. South Korea
  • 9.11. Taiwan
  • 9.12. Thailand
  • 9.13. Vietnam

10. Europe, Middle East & Africa Auranofin Market

  • 10.1. Introduction
  • 10.2. Denmark
  • 10.3. Egypt
  • 10.4. Finland
  • 10.5. France
  • 10.6. Germany
  • 10.7. Israel
  • 10.8. Italy
  • 10.9. Netherlands
  • 10.10. Nigeria
  • 10.11. Norway
  • 10.12. Poland
  • 10.13. Qatar
  • 10.14. Russia
  • 10.15. Saudi Arabia
  • 10.16. South Africa
  • 10.17. Spain
  • 10.18. Sweden
  • 10.19. Switzerland
  • 10.20. Turkey
  • 10.21. United Arab Emirates
  • 10.22. United Kingdom

11. Competitive Landscape

  • 11.1. Market Share Analysis, 2023
  • 11.2. FPNV Positioning Matrix, 2023
  • 11.3. Competitive Scenario Analysis
    • 11.3.1. Arthritis Foundation Invests USD 1.1 Million in Refractory Rheumatoid Arthritis Research
  • 11.4. Strategy Analysis & Recommendation

12. Competitive Portfolio

  • 12.1. Key Company Profiles
  • 12.2. Key Product Portfolio

LIST OF FIGURES

  • FIGURE 1. AURANOFIN MARKET RESEARCH PROCESS
  • FIGURE 2. AURANOFIN MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL AURANOFIN MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL AURANOFIN MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. GLOBAL AURANOFIN MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. AURANOFIN MARKET DYNAMICS
  • FIGURE 7. GLOBAL AURANOFIN MARKET SIZE, BY FORM, 2023 VS 2030 (%)
  • FIGURE 8. GLOBAL AURANOFIN MARKET SIZE, BY FORM, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL AURANOFIN MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
  • FIGURE 10. GLOBAL AURANOFIN MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. AMERICAS AURANOFIN MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 12. AMERICAS AURANOFIN MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. UNITED STATES AURANOFIN MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 14. UNITED STATES AURANOFIN MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. ASIA-PACIFIC AURANOFIN MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 16. ASIA-PACIFIC AURANOFIN MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. EUROPE, MIDDLE EAST & AFRICA AURANOFIN MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA AURANOFIN MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. AURANOFIN MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 20. AURANOFIN MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. AURANOFIN MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL AURANOFIN MARKET SIZE, 2018-2023 (USD MILLION)
  • TABLE 4. GLOBAL AURANOFIN MARKET SIZE, 2024-2030 (USD MILLION)
  • TABLE 5. GLOBAL AURANOFIN MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 6. GLOBAL AURANOFIN MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 7. GLOBAL AURANOFIN MARKET SIZE, BY FORM, 2018-2023 (USD MILLION)
  • TABLE 8. GLOBAL AURANOFIN MARKET SIZE, BY FORM, 2024-2030 (USD MILLION)
  • TABLE 9. GLOBAL AURANOFIN MARKET SIZE, BY CAPSULE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 10. GLOBAL AURANOFIN MARKET SIZE, BY CAPSULE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 11. GLOBAL AURANOFIN MARKET SIZE, BY TABLET, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 12. GLOBAL AURANOFIN MARKET SIZE, BY TABLET, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 13. GLOBAL AURANOFIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 14. GLOBAL AURANOFIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 15. GLOBAL AURANOFIN MARKET SIZE, BY SERONEGATIVE RHEUMATOID ARTHRITIS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 16. GLOBAL AURANOFIN MARKET SIZE, BY SERONEGATIVE RHEUMATOID ARTHRITIS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 17. GLOBAL AURANOFIN MARKET SIZE, BY SEROPOSITIVE RHEUMATOID ARTHRITIS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 18. GLOBAL AURANOFIN MARKET SIZE, BY SEROPOSITIVE RHEUMATOID ARTHRITIS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 19. AMERICAS AURANOFIN MARKET SIZE, BY FORM, 2018-2023 (USD MILLION)
  • TABLE 20. AMERICAS AURANOFIN MARKET SIZE, BY FORM, 2024-2030 (USD MILLION)
  • TABLE 21. AMERICAS AURANOFIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 22. AMERICAS AURANOFIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 23. AMERICAS AURANOFIN MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 24. AMERICAS AURANOFIN MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 25. ARGENTINA AURANOFIN MARKET SIZE, BY FORM, 2018-2023 (USD MILLION)
  • TABLE 26. ARGENTINA AURANOFIN MARKET SIZE, BY FORM, 2024-2030 (USD MILLION)
  • TABLE 27. ARGENTINA AURANOFIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 28. ARGENTINA AURANOFIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 29. BRAZIL AURANOFIN MARKET SIZE, BY FORM, 2018-2023 (USD MILLION)
  • TABLE 30. BRAZIL AURANOFIN MARKET SIZE, BY FORM, 2024-2030 (USD MILLION)
  • TABLE 31. BRAZIL AURANOFIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 32. BRAZIL AURANOFIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 33. CANADA AURANOFIN MARKET SIZE, BY FORM, 2018-2023 (USD MILLION)
  • TABLE 34. CANADA AURANOFIN MARKET SIZE, BY FORM, 2024-2030 (USD MILLION)
  • TABLE 35. CANADA AURANOFIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 36. CANADA AURANOFIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 37. MEXICO AURANOFIN MARKET SIZE, BY FORM, 2018-2023 (USD MILLION)
  • TABLE 38. MEXICO AURANOFIN MARKET SIZE, BY FORM, 2024-2030 (USD MILLION)
  • TABLE 39. MEXICO AURANOFIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 40. MEXICO AURANOFIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 41. UNITED STATES AURANOFIN MARKET SIZE, BY FORM, 2018-2023 (USD MILLION)
  • TABLE 42. UNITED STATES AURANOFIN MARKET SIZE, BY FORM, 2024-2030 (USD MILLION)
  • TABLE 43. UNITED STATES AURANOFIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 44. UNITED STATES AURANOFIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 45. UNITED STATES AURANOFIN MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
  • TABLE 46. UNITED STATES AURANOFIN MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
  • TABLE 47. ASIA-PACIFIC AURANOFIN MARKET SIZE, BY FORM, 2018-2023 (USD MILLION)
  • TABLE 48. ASIA-PACIFIC AURANOFIN MARKET SIZE, BY FORM, 2024-2030 (USD MILLION)
  • TABLE 49. ASIA-PACIFIC AURANOFIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 50. ASIA-PACIFIC AURANOFIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 51. ASIA-PACIFIC AURANOFIN MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 52. ASIA-PACIFIC AURANOFIN MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 53. AUSTRALIA AURANOFIN MARKET SIZE, BY FORM, 2018-2023 (USD MILLION)
  • TABLE 54. AUSTRALIA AURANOFIN MARKET SIZE, BY FORM, 2024-2030 (USD MILLION)
  • TABLE 55. AUSTRALIA AURANOFIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 56. AUSTRALIA AURANOFIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 57. CHINA AURANOFIN MARKET SIZE, BY FORM, 2018-2023 (USD MILLION)
  • TABLE 58. CHINA AURANOFIN MARKET SIZE, BY FORM, 2024-2030 (USD MILLION)
  • TABLE 59. CHINA AURANOFIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 60. CHINA AURANOFIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 61. INDIA AURANOFIN MARKET SIZE, BY FORM, 2018-2023 (USD MILLION)
  • TABLE 62. INDIA AURANOFIN MARKET SIZE, BY FORM, 2024-2030 (USD MILLION)
  • TABLE 63. INDIA AURANOFIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 64. INDIA AURANOFIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 65. INDONESIA AURANOFIN MARKET SIZE, BY FORM, 2018-2023 (USD MILLION)
  • TABLE 66. INDONESIA AURANOFIN MARKET SIZE, BY FORM, 2024-2030 (USD MILLION)
  • TABLE 67. INDONESIA AURANOFIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 68. INDONESIA AURANOFIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 69. JAPAN AURANOFIN MARKET SIZE, BY FORM, 2018-2023 (USD MILLION)
  • TABLE 70. JAPAN AURANOFIN MARKET SIZE, BY FORM, 2024-2030 (USD MILLION)
  • TABLE 71. JAPAN AURANOFIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 72. JAPAN AURANOFIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 73. MALAYSIA AURANOFIN MARKET SIZE, BY FORM, 2018-2023 (USD MILLION)
  • TABLE 74. MALAYSIA AURANOFIN MARKET SIZE, BY FORM, 2024-2030 (USD MILLION)
  • TABLE 75. MALAYSIA AURANOFIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 76. MALAYSIA AURANOFIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 77. PHILIPPINES AURANOFIN MARKET SIZE, BY FORM, 2018-2023 (USD MILLION)
  • TABLE 78. PHILIPPINES AURANOFIN MARKET SIZE, BY FORM, 2024-2030 (USD MILLION)
  • TABLE 79. PHILIPPINES AURANOFIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 80. PHILIPPINES AURANOFIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 81. SINGAPORE AURANOFIN MARKET SIZE, BY FORM, 2018-2023 (USD MILLION)
  • TABLE 82. SINGAPORE AURANOFIN MARKET SIZE, BY FORM, 2024-2030 (USD MILLION)
  • TABLE 83. SINGAPORE AURANOFIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 84. SINGAPORE AURANOFIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 85. SOUTH KOREA AURANOFIN MARKET SIZE, BY FORM, 2018-2023 (USD MILLION)
  • TABLE 86. SOUTH KOREA AURANOFIN MARKET SIZE, BY FORM, 2024-2030 (USD MILLION)
  • TABLE 87. SOUTH KOREA AURANOFIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 88. SOUTH KOREA AURANOFIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 89. TAIWAN AURANOFIN MARKET SIZE, BY FORM, 2018-2023 (USD MILLION)
  • TABLE 90. TAIWAN AURANOFIN MARKET SIZE, BY FORM, 2024-2030 (USD MILLION)
  • TABLE 91. TAIWAN AURANOFIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 92. TAIWAN AURANOFIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 93. THAILAND AURANOFIN MARKET SIZE, BY FORM, 2018-2023 (USD MILLION)
  • TABLE 94. THAILAND AURANOFIN MARKET SIZE, BY FORM, 2024-2030 (USD MILLION)
  • TABLE 95. THAILAND AURANOFIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 96. THAILAND AURANOFIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 97. VIETNAM AURANOFIN MARKET SIZE, BY FORM, 2018-2023 (USD MILLION)
  • TABLE 98. VIETNAM AURANOFIN MARKET SIZE, BY FORM, 2024-2030 (USD MILLION)
  • TABLE 99. VIETNAM AURANOFIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 100. VIETNAM AURANOFIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 101. EUROPE, MIDDLE EAST & AFRICA AURANOFIN MARKET SIZE, BY FORM, 2018-2023 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA AURANOFIN MARKET SIZE, BY FORM, 2024-2030 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA AURANOFIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA AURANOFIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA AURANOFIN MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA AURANOFIN MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 107. DENMARK AURANOFIN MARKET SIZE, BY FORM, 2018-2023 (USD MILLION)
  • TABLE 108. DENMARK AURANOFIN MARKET SIZE, BY FORM, 2024-2030 (USD MILLION)
  • TABLE 109. DENMARK AURANOFIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 110. DENMARK AURANOFIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 111. EGYPT AURANOFIN MARKET SIZE, BY FORM, 2018-2023 (USD MILLION)
  • TABLE 112. EGYPT AURANOFIN MARKET SIZE, BY FORM, 2024-2030 (USD MILLION)
  • TABLE 113. EGYPT AURANOFIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 114. EGYPT AURANOFIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 115. FINLAND AURANOFIN MARKET SIZE, BY FORM, 2018-2023 (USD MILLION)
  • TABLE 116. FINLAND AURANOFIN MARKET SIZE, BY FORM, 2024-2030 (USD MILLION)
  • TABLE 117. FINLAND AURANOFIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 118. FINLAND AURANOFIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 119. FRANCE AURANOFIN MARKET SIZE, BY FORM, 2018-2023 (USD MILLION)
  • TABLE 120. FRANCE AURANOFIN MARKET SIZE, BY FORM, 2024-2030 (USD MILLION)
  • TABLE 121. FRANCE AURANOFIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 122. FRANCE AURANOFIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 123. GERMANY AURANOFIN MARKET SIZE, BY FORM, 2018-2023 (USD MILLION)
  • TABLE 124. GERMANY AURANOFIN MARKET SIZE, BY FORM, 2024-2030 (USD MILLION)
  • TABLE 125. GERMANY AURANOFIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 126. GERMANY AURANOFIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 127. ISRAEL AURANOFIN MARKET SIZE, BY FORM, 2018-2023 (USD MILLION)
  • TABLE 128. ISRAEL AURANOFIN MARKET SIZE, BY FORM, 2024-2030 (USD MILLION)
  • TABLE 129. ISRAEL AURANOFIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 130. ISRAEL AURANOFIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 131. ITALY AURANOFIN MARKET SIZE, BY FORM, 2018-2023 (USD MILLION)
  • TABLE 132. ITALY AURANOFIN MARKET SIZE, BY FORM, 2024-2030 (USD MILLION)
  • TABLE 133. ITALY AURANOFIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 134. ITALY AURANOFIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 135. NETHERLANDS AURANOFIN MARKET SIZE, BY FORM, 2018-2023 (USD MILLION)
  • TABLE 136. NETHERLANDS AURANOFIN MARKET SIZE, BY FORM, 2024-2030 (USD MILLION)
  • TABLE 137. NETHERLANDS AURANOFIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 138. NETHERLANDS AURANOFIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 139. NIGERIA AURANOFIN MARKET SIZE, BY FORM, 2018-2023 (USD MILLION)
  • TABLE 140. NIGERIA AURANOFIN MARKET SIZE, BY FORM, 2024-2030 (USD MILLION)
  • TABLE 141. NIGERIA AURANOFIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 142. NIGERIA AURANOFIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 143. NORWAY AURANOFIN MARKET SIZE, BY FORM, 2018-2023 (USD MILLION)
  • TABLE 144. NORWAY AURANOFIN MARKET SIZE, BY FORM, 2024-2030 (USD MILLION)
  • TABLE 145. NORWAY AURANOFIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 146. NORWAY AURANOFIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 147. POLAND AURANOFIN MARKET SIZE, BY FORM, 2018-2023 (USD MILLION)
  • TABLE 148. POLAND AURANOFIN MARKET SIZE, BY FORM, 2024-2030 (USD MILLION)
  • TABLE 149. POLAND AURANOFIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 150. POLAND AURANOFIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 151. QATAR AURANOFIN MARKET SIZE, BY FORM, 2018-2023 (USD MILLION)
  • TABLE 152. QATAR AURANOFIN MARKET SIZE, BY FORM, 2024-2030 (USD MILLION)
  • TABLE 153. QATAR AURANOFIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 154. QATAR AURANOFIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 155. RUSSIA AURANOFIN MARKET SIZE, BY FORM, 2018-2023 (USD MILLION)
  • TABLE 156. RUSSIA AURANOFIN MARKET SIZE, BY FORM, 2024-2030 (USD MILLION)
  • TABLE 157. RUSSIA AURANOFIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 158. RUSSIA AURANOFIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 159. SAUDI ARABIA AURANOFIN MARKET SIZE, BY FORM, 2018-2023 (USD MILLION)
  • TABLE 160. SAUDI ARABIA AURANOFIN MARKET SIZE, BY FORM, 2024-2030 (USD MILLION)
  • TABLE 161. SAUDI ARABIA AURANOFIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 162. SAUDI ARABIA AURANOFIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 163. SOUTH AFRICA AURANOFIN MARKET SIZE, BY FORM, 2018-2023 (USD MILLION)
  • TABLE 164. SOUTH AFRICA AURANOFIN MARKET SIZE, BY FORM, 2024-2030 (USD MILLION)
  • TABLE 165. SOUTH AFRICA AURANOFIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 166. SOUTH AFRICA AURANOFIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 167. SPAIN AURANOFIN MARKET SIZE, BY FORM, 2018-2023 (USD MILLION)
  • TABLE 168. SPAIN AURANOFIN MARKET SIZE, BY FORM, 2024-2030 (USD MILLION)
  • TABLE 169. SPAIN AURANOFIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 170. SPAIN AURANOFIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 171. SWEDEN AURANOFIN MARKET SIZE, BY FORM, 2018-2023 (USD MILLION)
  • TABLE 172. SWEDEN AURANOFIN MARKET SIZE, BY FORM, 2024-2030 (USD MILLION)
  • TABLE 173. SWEDEN AURANOFIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 174. SWEDEN AURANOFIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 175. SWITZERLAND AURANOFIN MARKET SIZE, BY FORM, 2018-2023 (USD MILLION)
  • TABLE 176. SWITZERLAND AURANOFIN MARKET SIZE, BY FORM, 2024-2030 (USD MILLION)
  • TABLE 177. SWITZERLAND AURANOFIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 178. SWITZERLAND AURANOFIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 179. TURKEY AURANOFIN MARKET SIZE, BY FORM, 2018-2023 (USD MILLION)
  • TABLE 180. TURKEY AURANOFIN MARKET SIZE, BY FORM, 2024-2030 (USD MILLION)
  • TABLE 181. TURKEY AURANOFIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 182. TURKEY AURANOFIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 183. UNITED ARAB EMIRATES AURANOFIN MARKET SIZE, BY FORM, 2018-2023 (USD MILLION)
  • TABLE 184. UNITED ARAB EMIRATES AURANOFIN MARKET SIZE, BY FORM, 2024-2030 (USD MILLION)
  • TABLE 185. UNITED ARAB EMIRATES AURANOFIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 186. UNITED ARAB EMIRATES AURANOFIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 187. UNITED KINGDOM AURANOFIN MARKET SIZE, BY FORM, 2018-2023 (USD MILLION)
  • TABLE 188. UNITED KINGDOM AURANOFIN MARKET SIZE, BY FORM, 2024-2030 (USD MILLION)
  • TABLE 189. UNITED KINGDOM AURANOFIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 190. UNITED KINGDOM AURANOFIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 191. AURANOFIN MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 192. AURANOFIN MARKET, FPNV POSITIONING MATRIX, 2023